Literature DB >> 11072203

Cervical cancer screening in Belgium.

M Arbyn1, H Van Oyen.   

Abstract

A description is given of the burden of cervical cancer and the status of screening in Belgium until 1998. Screening is essentially opportunistic and generally performed at yearly intervals. A programme for organised screening - promoting one cervical smear every 3 years for women aged between 25 and 64 years - is being set up in the Flemish Region alone. Important progress has been made concerning the development of technical guidelines on the collection of an adequate Papanicolaou (Pap) smear, uniform terminology for the cytological report and the follow-up of positive tests. The implementation of the programme is confined to the provinces that are instructed to make women and physicians aware of the screening policy. The establishment of a screening register, allowing for individualised invitation of women, was hampered by strict privacy laws and by the heterogeneity of software used for data entry in cytological laboratories. The impact of the Flemish programme was further limited since the reimbursement of smear taking by a gynaecologist or a general practitioner (GP) and the cytological reading are not conditioned by the respect of guidelines. This is due to the fact that the organisation of preventive healthcare and the financing of medical activities concerns distinct authorities. The coverage of the target population is good in Flanders (82.3% according to certain estimates), but is achieved at the expense of an important amount of over-screening. The coverage is lower in the Walloon and the Capital Region. Rationalisation of the policy regarding cancer screening involving all concerned authorities of the country is necessary.

Entities:  

Mesh:

Year:  2000        PMID: 11072203     DOI: 10.1016/s0959-8049(00)00308-7

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  9 in total

1.  Multiple human papillomavirus infections with high viral loads are associated with cervical lesions but do not differentiate grades of cervical abnormalities.

Authors:  Markus Schmitt; Christophe Depuydt; Ina Benoy; Johannes Bogers; Jerome Antoine; Marc Arbyn; Michael Pawlita
Journal:  J Clin Microbiol       Date:  2013-02-27       Impact factor: 5.948

2.  Positive test results motivate GPs to continue screening in a chlamydia prevalence study.

Authors:  Veronique Verhoeven; Dirk Avonts; Roy Remmen; Hugo Van Puymbroeck; Paul Van Royen
Journal:  Br J Gen Pract       Date:  2003-08       Impact factor: 5.386

3.  A cross-sectional, multicentre, epidemiological study on human papillomavirus (HPV) type distribution in adult women diagnosed with invasive cervical cancer in Belgium.

Authors:  W A A Tjalma; X B Trinh; M Rosenlund; A P Makar; F Kridelka; D Rosillon; P A Van Dam; S Collas De Souza; K Holl; P Simon; D Jenkins
Journal:  Facts Views Vis Obgyn       Date:  2015

4.  The impact of regional screening policies on the diffusion of cancer screening participation in Belgium: time trends in educational inequalities in Flanders and Wallonia.

Authors:  Barbara Willems; Piet Bracke
Journal:  BMC Health Serv Res       Date:  2018-12-04       Impact factor: 2.655

5.  High burden of breast cancer in Belgium: recent trends in incidence (1999-2006) and historical trends in mortality (1954-2006).

Authors:  Françoise Renard; Liesbet Van Eycken; Marc Arbyn
Journal:  Arch Public Health       Date:  2011-10-24

6.  Thin-layer liquid-based cervical cytology and PCR for detecting and typing human papillomavirus DNA in Flemish women.

Authors:  C E Depuydt; A J Vereecken; G M Salembier; A S Vanbrabant; L A Boels; E van Herck; M Arbyn; K Segers; J J Bogers
Journal:  Br J Cancer       Date:  2003-02-24       Impact factor: 7.640

7.  Validation of intra- and inter-laboratory reproducibility of the Xpert HPV assay according to the international guidelines for cervical cancer screening.

Authors:  Ajmal Akbari; Davy Vanden Broeck; Ina Benoy; Elizaveta Padalko; Johannes Bogers; Marc Arbyn
Journal:  Virol J       Date:  2018-10-29       Impact factor: 4.099

8.  Never and under cervical cancer screening in Switzerland and Belgium: trends and inequalities.

Authors:  Vladimir Jolidon; Vincent De Prez; Barbara Willems; Piet Bracke; Stéphane Cullati; Claudine Burton-Jeangros
Journal:  BMC Public Health       Date:  2020-10-07       Impact factor: 3.295

9.  Attendance at cervical cancer screening and use of diagnostic and therapeutic procedures on the uterine cervix assessed from individual health insurance data (Belgium, 2002-2006).

Authors:  Marc Arbyn; Valérie Fabri; Marleen Temmerman; Cindy Simoens
Journal:  PLoS One       Date:  2014-04-01       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.